Literature DB >> 20012158

Intravitreal bevacizumab to facilitate vitrectomy in idiopathic ischaemic retinal vasculitis.

Roger Wong1, Bhaskar Gupta, Miles R Stanford, D Alistair H Laidlaw.   

Abstract

To describe the use of intravitreal bevacizumab in idiopathic retinal vasculitis prior to vitrectomy and delamination. A young healthy male presented with idiopathic retinal vasculitis. His condition was refractory to panretinal photocoagulation and systemic steroids. The progression of his condition necessitated vitrectomy and delamination. Intravitreal bevacizumab was used to facilitate the surgical procedure, with effective results. Intravitreal bevacizumab can be an adjunct to vitrectomy in idiopathic retinal vasculitis. However, caution must be taken due to its ability to promote fibrosis and to produce further tractional and/or rhegmatogenous retinal detachment. Further controlled studies are required to understand its benefits in managing complicated idiopathic retinal vasculitis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20012158     DOI: 10.1007/s10792-009-9329-4

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  4 in total

1.  A long-term follow-up of Eales' disease.

Authors:  Leyla S Atmaca; Figen Batioglu; Pelin Atmaca Sonmez
Journal:  Ocul Immunol Inflamm       Date:  2002-09       Impact factor: 3.070

2.  Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab.

Authors:  Atul Kumar; Subijay Sinha
Journal:  Can J Ophthalmol       Date:  2007-04       Impact factor: 1.882

3.  Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.

Authors:  Robert L Avery; Joel Pearlman; Dante J Pieramici; Melvin D Rabena; Alessandro A Castellarin; Ma'an A Nasir; Matthew J Giust; Robert Wendel; Arun Patel
Journal:  Ophthalmology       Date:  2006-10       Impact factor: 12.079

4.  Massive vascular endothelium growth factor (VEGF) expression in Eales' disease.

Authors:  Yannis Perentes; Chi Chao Chan; Etienne Bovey; Sylvie Uffer; Carl P Herbort
Journal:  Klin Monbl Augenheilkd       Date:  2002-04       Impact factor: 0.700

  4 in total
  1 in total

1.  Intravitreal bevacizumab in treatment of retinal neovascularization from tuberculous retinal vasculitis.

Authors:  Theeratach Sriboonnark; Sutasinee Boonsopon; Nattaporn Tesavibul; Supinda Leeamornsiri; Pitipol Choopong
Journal:  Int J Ophthalmol       Date:  2017-10-18       Impact factor: 1.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.